Akebia Therapeutics Inc (NASDAQ:AKBA) price on current trading day, rose 3.11% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.99.
A look at the stock’s price movement, the level at last check in today’s session was $1.93, moving within a range at $1.92 and $2.005. The beta value (5-Year monthly) was 0.734. Turning to its 52-week performance, $2.48 and $0.80 were the 52-week high and 52-week low respectively. Overall, AKBA moved 8.15% over the past month.
Akebia Therapeutics Inc’s market cap currently stands at around $434.18 million, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 39.02M for the company’s revenue for the quarter, with a low and high estimate of 35.25M and 43.42M respectively. The average forecast suggests down to a -30.56% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 152.71M, representing a -21.53% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AKBA is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend AKBA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AKBA’s current price about 6.33% and 4.29% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.09, while 7-day volatility ratio is 5.83% and 4.79% in the 30-day chart. Further, Akebia Therapeutics Inc (AKBA) has a beta value of 0.73, and an average true range (ATR) of 0.09. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $6 and high of $7. Looking at the price targets, the low is -201.51% off recent price level in today’s trading while to achieve the yearly target high, it has to move -251.76%. Nonetheless, investors will most likely welcome a -226.63% jump to $6.5 which is the analysts’ median price.
If we refocus on Akebia Therapeutics Inc (NASDAQ:AKBA), historical trading data shows that trading volumes averaged 2.1 over the past 10 days and 2.25 million over the past 3 months. The company’s latest data on shares outstanding shows there are 211.54 million shares.
The 4.85% of Akebia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 24.85% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 16.68 million on 2024-12-31, giving us a short ratio of 7.9. The data shows that as of 2024-12-31 short interest in Akebia Therapeutics Inc (AKBA) stood at 771.99996 of shares outstanding, with shares short rising to 11.56 million registered in 2024-11-29. Current price change has pushed the stock 4.74% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AKBA stock continues to rise going into the next quarter.
